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ABSTRACT
Objectives: This study aims to investigate the effects of blood pressure control level on maternal and perinatal outcomes 
in pregnant women with mild to moderate gestational hypertension (GHp).
Material and methods: A total of 344 pregnant women who initially diagnosed as mild to moderate gestational hyperten-
sion were recruited in this study. They were divided into 4 groups according to the stabilized blood pressure level (BPL) 
during pregnancy. The clinical parameters and the incidence of adverse pregnancy outcomes were compared among the 
four groups. The association between blood pressure levels and relative factors were analyzed using the χ2 test. Multivariate 
logistic regression analysis was adopted for risk factors associated with adverse pregnancy outcomes. 
Results: The results showed the prevalence of obesity was significantly associated with blood pressure levels of mild-mod-
erate GHp pregnant women (p = 0.029). The incidence of severe GHp, SPE in group A, group B, and group C were statistically 
significant (p < 0.001, p = 0.041, respectively). In the patients who used drugs to control BPL, the incidence of severe GHp 
has a significant association with the initial blood pressure levels (p = 0.004). However, no significant difference was found 
in the incidence of sPE, PE + Upro, and SGA (all p > 0.05). Multivariate logistic regression analyses results showed that the 
gestational factor BPL was an independent risk factor for the incidence of sGHp. The AMA, primigravida, gestational BPL, and 
edema were risk factors for the incidence of preeclampsia with proteinuria. To the incidence of sPE, gestational BPL is the 
independent risk factor. Finally, preeclampsia anamnesis and FGR trend are the high-risk parameters to the incidence of SGA. 
Conclusions: Timely management and control of blood pressure in pregnant women with mild to moderate GHp were 
beneficial to reduce the occurrence of severe GHp and sPE, but the incidence of SGA does not affected. 
Key words: blood pressure level; pregnancy; maternal outcome; perinatal outcome; preeclampsia; hypertension in preg-
nancy; adverse pregnant outcomes
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INTRODUCTION
Hypertensive disorder complicating pregnancy (HDCP) 
is a common complication of pregnancy, with a spectrum of 
conditions that include chronic hypertension, gestational 
hypertension (GHp), preeclampsia (PE), severe PE (sPE), ec-
lampsia, and chronic hypertension with preeclampsia. HDCP 
is one of the main causes of maternal and perinatal morbidity 
and mortality, which seriously affects the health of mother 
and fetal [1, 2]. Pregnancy with hypertension affected 6–8% 
of pregnancies in the USA, and about 5.22% of pregnancies 
in China [3, 4]. In addition to maternal cerebrovascular and 
cardiac complications, HDCP is also associated with small 
for gestational age (SGA) infants and preterm birth [5–7]. 
Previous study by Buchbinder A et al. [6] showed the adverse 
perinatal outcomes were higher in women with severe ges-
tational hypertension than in mild preeclampsia. A study by 
Mudjari NS et al. [8] pointed that the management of hyper-
tension in pregnancy by preventing women from getting the 
risks of increased blood pressure (BP) can reduce maternal 
and perinatal morbidity and mortality. 
The prevention, early diagnosis, and treatment of HDCP 
can reduce the risk of maternal and fetal complications 
[9–11]. In most regions of the world, severe gestational 
hypertension was diagnosed when the blood pressure dur-
ing pregnancy is more than 160/110 mm Hg [12–14]. It has 
reached a consensus on the antihypertensive treatment 
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of severe gestational hypertension, and it is necessary to 
control the blood pressure when the severe gestational hy-
pertension occurs. However, there are still different views on 
when the treatment of hypertension should be initiated for 
pregnant women with mild-moderate gestational hyperten-
sion (systolic blood pressure 140–159 mm Hg and diastolic 
blood pressure 90–109 mm Hg). According to the report of 
the American College of Obstetricians and Gynecologists’ 
Task Force on hypertension in pregnancy, it is suggested that 
anti-hypertensive medications not be administered for wom-
en with mild gestational hypertension or preeclampsia with 
a persistent blood pressure of less than 160/110 mm Hg [12]. 
Whereas some other countries, such as Canada, Australia, 
China, and so on, believe that the treatment of anti-hyper-
tensive can also be considered in women with mild-moder-
ate gestational hypertensive [13–15]. Therefore, to optimize 
the management of blood pressure in pregnancies with 
mild-moderate hypertensive is necessary for reducing ma-
ternal and perinatal morbidity and mortality.
Objectives
In the present study, we compared the clinical factors 
associated with GHp and incidence rates of severe GHp, 
preeclampsia with proteinuria (PE + Upro), sPE and SGA. 
This study aims to investigate the effects of blood pres-
sure control level on perinatal outcomes in women with 
mild-moderate gestational hypertension. 
MATERIAL AND METHODS
Study Population
A total of 344 pregnant women (aged from 21 to 
44, the average age was 30.15 ± 5.15 years; gestational 
age of 20–32 weeks, the average gestational age was 
25.75 ± 2.24 weeks) were included between January 
2012 and December 2016 in The Second Affiliated Hos-
pital and Yuying Children’s Hospital of Wenzhou Medical 
University (Wenzhou, Zhejiang). Eligible women were those 
who have had regular antenatal examinations, carried the 
pregnancy to term, and initially diagnosed with mild to 
moderate gestational hypertensive. The women with multi-
ple pregnancies, fetal chromosomal abnormalities, placenta 
previa, spontaneous abortion, or induced abortion before 
20 weeks of pregnancy were excluded. The clinical infor-
mation was collected in this study including maternal age, 
maternal pre-pregnancy BMI, recurrent spontaneous abor-
tion (RSA), previous history of preeclampsia, and maternal 
syndrome (such as nephritis and kidney disease syndrome, 
thyroid disorder, glucose metabolism, immune system dis-
ease, and polycystic ovarian syndrome). Obesity is usually 
classified by BMI. According to the criteria recommended 
by Working Group on Obesity in China, BMI was grouped 
into three categories: normal weight (< 24.0 kg/m2), over-
weight (≥ 24.0 and < 28 kg/m2), and obesity (≥ 28.0 kg/m2). 
The detailed clinical characteristics were summarized in 
Table 1 and Table 2. The study protocol was approved by 
the Ethical Approval of The Second Affiliated Hospital and 
Yuying Children’s Hospital of Wenzhou Medical University. 
All participants signed informed consent. 
Definition and classification
According to the stabilized blood pressure level (BPL) 
during pregnancy, the participants were divided into four 
groups, including A, B, C, and D group. Group A includes 
135 pregnancy women (BPL < 130/80 mm Hg). Group B 
includes 160 participants with systolic blood pressure be-
tween 130 and 139 mm Hg, and diastolic blood pressure be-
tween 80 and 89 mm Hg. Group C obtained 46 participants 
with systolic blood pressure between 140 and 149 mm Hg, 
and diastolic blood pressure between 90 and 99 mm Hg. 
Group D includes 3 participants with systolic blood pressure 
between 150 and 159 mm Hg, and diastolic blood pressure 
between 100 and 109 mm Hg. 
Diagnostic Criteria
The diagnosis of HDCP, including GHp, PE, and sPE, was 
based on the diagnosis and treatment guideline of hyper-
tensive disorders during pregnancy [16]. Pregnancy compli-
cations, obtaining gestational diabetes mellitus (GDM), small 
for gestational age (SGA), fetal growth restriction (FGR), poly-
cystic ovarian syndrome (PCOS), immune system disease, 
and other gestational complications, were also analyzed in 
the study. The diagnosis of GDM was based on the results of 
an oral glucose tolerance test [17]. Wessel’s modified criteria 
were used to define the SGA infants. The predictive factors 
of PE mainly include prehypertension, excess body mass 
(> 0.5 kg per week), edema, hypoalbuminemia, decreased 
platelet level, and FGR trend. PCOS was defined according 
to the consensus on women’s health aspects of PCOS [18]. 
Blood pressure control method
The management of blood pressure during pregnancy 
was controlled using oral drug therapeutic approach (la-
betalol or nifedipine) and lifestyle interventions. Lifestyle 
interventions, such as rest, diet control, adjustment of 
mental and environmental factors, are of proven benefit 
in gestational hypertensive. Among the participants in this 
study, there are 48 pregnancy women used therapeutic 
drug approach to control the blood pressure. What’s more, 
the placental and fetal growth status were detected during 
the anti-hypertensive treatment.
Statistical analysis
Statistical analysis was carried out using SPSS soft-
ware (SPSS, Inc., Chicago, IL, USA). Data are expressed as 
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mean ± SD. The clinical profile and incidence of severe GHp, 
preeclampsia with proteinuria (PE + Upro), sPE, SGA were 
compared among the four groups. The differences between 
two groups were examined by paired student’s t tests. Ma-
ternal and perinatal outcomes were compared using χ2 test 
and multivariable logistic regression to control for potential 
Table 1. The relationship between blood pressure level and parameters of GHp women
Parameters Cases (n = 344)
GHp women groups
p
A (n = 135) B (n = 160) C (n = 46) D (n = 3)
Gestational age 25.75 ± 2.24 25.93 ± 2.18 25.46 ± 2.18 26.20 ± 2.71 26.33 ± 3.51 0.134
RSA 0.951
No 323 126 151 43 3
Yes 21 9 9 3 0
AMA 0.070
No 254 100 125 27 2
Yes 90 35 35 19 1
Obesity 0.029
No 301 124 140 35 2
Yes 43 11 20 2 1
PE anamnesis 0.182
No 335 134 155 43 3
Yes 9 1 5 3 0
Primigravida 0.056
No 169 62 75 29 3
Yes 175 73 85 17 0
Primiparity 0.524
No 29 8 16 5 0
Yes 315 127 144 41 3
Pregnancy complications 0.370
No 204 82 95 24 3
Yes 140 53 65 22 0
RSA — recurrent spontaneous abortion; AMA — advanced maternal age (pregnant women aged 35 years or over)
Table 2. Prevalence of adverse pregnancy outcomes in relation to blood pressure levels
Outcomes Cases (n = 344)
GHp women groups
p
A (n = 135) B (n = 160) C (n = 46) D (n = 3)
Severe GHp < 0.001
No 322 134 149 36 3
Yes 22 1 11 10 0
PE + Upro 0.311
No 242 98 113 28 3
Yes 102 37 47 18 0
sPE 0.041
No 296 122 137 34 3
Yes 48 13 23 12 0
SGA 0.813
No 314 124 144 43 3
Yes 30 11 16 3 0
Severe GHp — severe gestational hypertension; PE + Upro — preeclampsia with proteinuria; sPE — severe preeclampsia; SGA — small for gestational age
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risk factors. P value less than 0.05 was considered to be 
statistically significant.
RESULTS
Association between blood pressure level and 
clinical characteristics of pregnant women
In the present study, we compared the clinical character-
istics of four groups of pregnant women with mild-moderate 
GHp. The prevalence of obesity among pregnant women 
in group A is 8.1% (11/135), 12.5% (20/160) in group B, 
23.9% (11/46) in group C, and 33.3% (1/3) in group D, which 
increased following the rising of BPL. The results showed 
the prevalence of obesity was significantly associated with 
blood pressure levels of mild-moderate GHp pregnant wom-
en (p = 0.029, Tab. 1). However, no positive associations were 
found with other clinical characteristics, such as gestational 
age, RSA, advanced maternal age (AMA; pregnant women 
aged 35 years or over), PE anamnesis, primigravida, primi-
parity, pregnancy complications (all p > 0.05, Tab. 1).
Prevalence of adverse pregnancy outcomes in 
relation to blood pressure levels
We also analyzed the incidence of adverse pregnancy 
outcomes in four groups of pregnant women. In group D, 
there was no occurrence of adverse pregnancy outcome. 
The incidence of severe GHp in group A (0.7%, 1/135), group 
B (6.9%, 11/160), and group C (21.7%, 10/46) was statistically 
significant (p < 0.001, Tab. 2). The incidence of sPE was also 
found (a significant difference among group A, group B, and 
group C) (p = 0.041, Tab. 2). However, there was no significant 
difference of incidence of preeclampsia with proteinuria 
(PE + Upro) and SGA (all p > 0.05).  
The occurrence of adverse pregnancy outcomes 
in pregnant women with mild-moderate GHp 
after anti-hypertensive 
In the present study, 48 participants were given an-
ti-hypertensive drugs to control blood pressure. Among 
the pregnant women who used anti-hypertensive drugs, 
10 pregnant women had BPL less than 130/80 mm Hg, 
25 participants had a BPL of (130–139)/(80–89) mm Hg, and 
13 pregnant women had a BPL of (140–149)/(90–99) mm 
Hg. As shown in Table 3, the incidence rates of severe GHp 
and sPE in pregnant women with different pregnancy blood 
pressure levels were significantly different (all p < 0.05). 
Among different pregnancy blood pressure levels groups, 
there was no dramatical difference in the incidence of preec-
lampsia with proteinuria and SGA (all p > 0.05).
As shown in Table 4, with the increase of initial blood 
pressure levels, the incidence of severe GHp (3/23, 7/15, 7/10) 
is significantly increased, which has a significant difference 
(p = 0.004). However, no significant difference was found in 
the incidence of sPE, PE + Upro, and SGA (all p > 0.05). 
Risk parameters related to the incidence of 
adverse pregnancy outcomes 
To analyze the risk parameters correlated with adverse 
pregnancy outcomes, we used the logistic regression 
analysis. As shown in Table 5, the factors gestational BPL 
(OR = 2.958, 95% CI = 1.293–6.766, p = 0.010) is the high 
risk parameters that significantly related to the incidence of 
sGHp. The AMA (OR = 0.112, 95% CI = 0.047–0.265, p < 0.001), 
primigravida (OR = 0.129, 95% CI = 0.070–0.238, p < 0.001), 
gestational BPL (OR = 1.903, 95% CI = 1.224 - 2.959, p = 0.004), 
and edema (OR = 2.698, 95% CI = 1.360–5.351, p = 0.005) 
Table 3. Comparison of pregnancy blood pressure levels and prevalence of adverse pregnancy outcomes in 48 mild-moderate GHp women 
using anti-hypertensive drugs
Outcomes Cases (n = 48)
Prenatal BPL (mm Hg)
p
< 130/80 (130–139)/(80–89) (140–149)/(90–99)
Severe GHp 0.007
No 31 9 18 4
Yes 17 1 7 9
PE + Upro 0.168
No 24 7 13 4
Yes 24 3 12 9
sPE 0.042
No 28 8 16 4
Yes 20 2 9 9
SGA 0.709
No 39 9 20 10
Yes 9 1 5 3
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are risk factors for the incidence of preeclampsia with pro-
teinuria. To the incidence of sPE, gestational BPL (OR = 1.814, 
95% CI = 1.060–3.104, p = 0.030) is the independent risk 
factor. Finally, preeclampsia anamnesis (OR = 6.866, 
95% CI = 1.347–34.998, p = 0.021) and FGR trend (OR = 3.993, 
95% CI = 1.565–10.189, p = 0.004) are the high risk param-
eters that dramatically associated with the incidence of SGA. 
DISCUSSION
Gestational hypertensive is one of the common compli-
cations in pregnancy, which is initial occurred hypertension 
after 20 weeks of gestation and will return to normal within 
12 weeks after delivery. Light GHp can be asymptomatic or 
mild dizziness, slightly elevated blood pressure, accompa-
nied by edema or mild proteinuria, severe GHp may cause 
important organs injury, occur PE or eclampsia. PE and 
eclampsia are the main cause of adverse maternal and peri-
natal outcomes, such as intrauterine growth restriction and 
preterm birth [19, 20]. The study by Schokker SA et al. [21] 
showed previous hypertensive disorders of pregnancy was 
an independent risk factor for later vascular morbidity. 
Therefore, controlling pregnancy blood pressure can avoid 
organ or placenta injury and reduce the occurrence of seri-
ous adverse maternal and perinatal outcomes.
Previous studies have shown that the treatment of se-
vere GHp can minimize the fluctuation of blood pressure 
during pregnancy and reduce the future risk of vascular 
(such as cerebrovascular and/or cardiovascular disease) 
disease [21–25]. A study by Choi DJ et al. [22] showed that 
a family history of premature cardiovascular disease was sig-
nificantly associated with gestational hypertensive disease. 
The study by Abalos E et al. [23] showed that with the use of 
antihypertensive drugs could reduce the risk of developing 
severe hypertension, but no clear differences in the risk of 
other developing outcomes were found. Molvi SN et al. [24] 
also found antihypertensive therapy was associated with 
a lower incidence of severe pregnancy-induced hyperten-
sion, proteinuria, SGA babies, as well as some other maternal 
and fetal-neonatal non-fatal adverse events. A previous 
study suggested that anti-hypertensive treatment when 
BPL > 140/90 mm Hg, coupled with close fetal monitoring, 
might result in both improved fetal outcome, as well as de-
creasing immediate maternal complications and permanent 
vascular injury [25]. However, whether anti-hypertensive 
drug therapy for women with mild or moderate GHp is still 
controversial. 
In the present study, we analyzed the clinical param-
eters of pregnant women with mild to moderate GHp. We 
found the prevalence of obesity was significantly associated 
with blood pressure levels of mild-moderate GHp pregnant 
women. Some studies have indicated obesity was associated 
Table 4. Comparison of initial blood pressure levels and prevalence of adverse pregnancy outcomes in 48 mild-moderate GHp women using 
anti-hypertensive drugs
Outcomes Cases (n = 48)
Initial BPL (mm Hg)
p
(140–149)/(90–99) (150–159)/(100–109) ≥ 160/110
Severe GHp 0.004
No 31 20 8 3
Yes 17 3 7 7
PE + Upro 0.651
No 24 13 7 4
Yes 24 7 8 6
sPE 0.392
No 28 14 10 4
Yes 20 9 5 6
SGA 0.805
No 39 18 13 8
Yes 9 5 2 2
Table 5. Logistic regression analysis of factors contributing to 
adverse pregnancy outcomes
Outcomes Variables p OR 95% CI
sGHp Gestational BPL 0.010 2.958 1.293- 6.766
PE + Upro AMA < 0.001 0.112 0.047–0.265
Primigravida < 0.001 0.129 0.070–0.238
Gestational BPL 0.004 1.903 1.224–2.959
Edema 0.005 2.698 1.360–5.351
sPE Gestational BPL 0.030 1.814 1.060–3.104
SGA PE anamnesis 0.020 6.866 1.347–34.998
FGR trend 0.004 3.993 1.565–10.189
FGR trend — uterine length and abdominal circumference were all below the 
10th percentile for 3 consecutive weeks
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with blood pressure and increased risks of GHp. For instance, 
Gaillard R et al. [26] suggested maternal obesity and morbid 
obesity were strongly associated with the risk of gestational 
hypertensive disorders. Pregnancy is a period of substantial 
change in blood pressure, with physiological blood pres-
sure decreasing before the middle stage of pregnancy, and 
then increasing until delivery [27–29]. In this study, we also 
analyzed the incidence of adverse pregnancy outcomes in 
pregnant women with different BPL. The results showed that 
the incidence of severe GHp in group A (0.7%, 1/135), group 
B (6.9%, 11/160), and group C (21.7%, 10/46) was statistically 
significant, which showed an increasing trend with the BPL 
level. The incidence of sPE was consistent with that of severe 
GHp. But in group D, there was no occurrence of adverse 
pregnancy outcome, which might be related to only 3 cases, 
as the small sample size was prone to bias. Then we further 
investigated the adverse pregnancy outcomes in pregnant 
women who took BPL medications. Among 48 pregnant 
women who used anti-hypertensive drugs, 10 pregnant 
women had BPL less than 130/80 mm Hg, 25 participants 
had a BPL of (130–139)/(80–89) mm Hg, and 13 pregnant 
women had a BPL of (140–149)/(90–99) mm Hg. After an-
ti-hypertensive treatment, the incidence rates of severe GHp 
and severe eclampsia in pregnant women with different 
pregnancy blood pressure levels were also found signifi-
cantly different. However, there was no dramatical difference 
in the incidence of preeclampsia with proteinuria and SGA. 
The occurrence and development of mild to moderate GHp 
may be influenced by multiple factors. Multivariate logistic 
regression analysis results showed gestational BPL was an in-
dependent risk factor for the incidence of severe GHp and 
sPE. Hence, low blood pressure during pregnancy in GHp 
women can help reduce the occurrence of severe GHp and 
sPE, and will not lead to increased incidence of SGA. 
What’s more, we analyzed initial blood pressure lev-
els and prevalence of adverse pregnancy outcomes in 
mild-moderate GHp women using anti-hypertensive 
drugs. The results showed that the incidence of preeclamp-
sia with proteinuria, sPE, and SGA have no significant dif-
ference with the initial BPL in mild to moderate pregnant 
women who had anti-hypertensive treatment, and only the 
difference in the incidence of severe GHp was statistically 
significant. The results indicated with the increase of initial 
blood pressure levels, the incidence of severe GHp (3/23, 
7/15, 7/10) was significantly increased. According to the 
multivariate logistic regression analysis results, the initial BPL 
was an independent risk factor for the incidence of severe 
GHp, which suggested timely management and control of 
blood pressure in pregnant women with mild to moderate 
GHp was beneficial to reduce the occurrence of severe GHp. 
The multivariate logistic regression analysis results also 
showed edema was risk factor that significantly associated 
with preeclampsia with proteinuria. The pregnant women 
with edema show a higher incidence of preeclampsia with 
proteinuria than those without edema. Therefore, it is nec-
essary to observe the occurrence of edema for preventing 
the incidence of PE. According to the results of detection 
of placental and fetal growth status during the anti-hyper-
tensive treatment, there was no affection to the incidence 
of SGA. Multivariate logistic regression analysis results show 
the factors gestational BPL is the high-risk parameters that 
significantly related to the incidence of sGHp. The AMA, 
primigravida, gestational BPL, and edema are risk factors 
for the incidence of preeclampsia with proteinuria. To the 
incidence of sPE, gestational BPL is an independent risk 
factor. Finally, preeclampsia anamnesis and FGR trend are 
the high-risk parameters that dramatically associated with 
the incidence of SGA. These results showed that the risk 
factors influencing the incidence of adverse pregnancy 
outcomes were very complicated. The gestational BPL was 
found significantly associated with the incidence of severe 
GHp, preeclampsia with proteinuria, and sPE. To control 
the gestational BPL is beneficial to delay the progression 
of severe GHp, and reduce the incidence of sPE. 
In considering the results of this study, some limitations 
need to be addressed. First, the sample size of patients is 
limited. A large number of subjects can improve the accu-
racy of the results. Second, part of the clinical data was not 
completed, and more parameters can be involved in the 
further analyses. Due to the limitations, further analyses are 
necessary for large research cohort and more parameters. 
CONCLUSIONS
In conclusion, timely management and control of blood 
pressure in pregnant women with mild to moderate GHp 
was beneficial to delay the progression of severe GHp, and 
reduce the occurrence of sPE. What’s more, there is no cor-
relation was found with the incidence of SGA. Meanwhile, 
due to the regular prenatal examination and the diversifica-
tion of diagnostic methods, mild to moderate GHp pregnant 
women can be timely diagnosed. 
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